House Democrats who want to empower the government to demand lower prices from drugmakers are concerned that moderates in their party are now emboldened to blunt their ambitious drug-pricing agenda.
Lawmakers pushing to fulfill their party’s longtime call to allow the government to negotiate with the pharmaceutical industry on the price of medicines watched with unease this week as a group of 10 moderate Democrats delayed a procedural vote for their party’s reconciliation bill, the vehicle for their $3.5 trillion economic expansion plan.
Their fear is that some of these same moderates may again band together to blunt the drug-pricing ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.